BTIG analyst Ryan Zimmerman maintained a Hold rating on Vicarious Surgical (RBOT – Research Report) on January 5. The company’s shares closed last Friday at $0.42.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 7.8% and a 45.40% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Stryker, and Avita Medical.
Currently, the analyst consensus on Vicarious Surgical is a Hold with an average price target of $1.00.
See the top stocks recommended by analysts >>
Based on Vicarious Surgical’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.33 million. In comparison, last year the company had a GAAP net loss of $1.45 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vicarious Surgical (RBOT) Company Description:
D8 Holdings Corp is a blank check company.
Read More on RBOT:
- Vicarious Surgical initiated with an Equal Weight at Morgan Stanley
- Vicarious Surgical price target lowered to $1.50 from $4 at Piper Sandler
- Vicarious Surgical downgraded to Neutral from Buy at BTIG
- Vicarious Surgical downgraded to Hold from Buy at Canaccord
- Vicarious Surgical sees FY23 cash burn $60M-$65M
